Barcelona-based Grifols SA will acquire Talecris Biotherapeutics Holdings Corp. for $3.4 billion in cash and stock, expanding its U.S. market share for blood-plasma products. Through the acquisition, Grifols gains sales of Gamunex, a treatment for three immune-system disorders, and Prolastin, the top-selling treatment for Alpha-1 antitrypsin deficiency, a condition that can lead to lung disease. The two products accounted for 77% of Talecris sales in the three months ended March 31. Talecr...